- Joined
- Sep 6, 2008
- Messages
- 4,720
I think there is truth to the 'young responder' effect, but we are entirely mistaken to simply dismiss this with a reductive 'a molecule is a molecule' argument. That only works in a theoretical vacuum.I think one thing people forget is, a lot of their amazing responses to their first bottle of these drugs was when they were younger, fresh, first time responding to AAS as well. Even if they got a hold of that amazing drug from the "good old day" now, they might not get the same effect as they did when they were at a time of their lifting life where gains were "fresh".
There are clear, material reasons why today's gray-market AAS can be biologically inferior. They are manufactured without GMP compliance, leading to structural failures that standard lab tests completely miss: unreacted chemical impurities, poor solid-state crystal polymorphism that ruins oral absorption, over-saturated harsh solvents that trigger systemic immune responses, and sloppy esterification that destabilizes blood serum levels.
This isn't just me dumping on underground labs; even multi-billion-dollar pharmaceutical corporations fail when they take shortcuts with the delivery matrix.
For instance, I shared before the infamous Teva generic Wellbutrin XL scandal proved that using a cheap, alternative time-release coating caused 'dose dumping', the active molecule was identical, but the delivery mechanism was broken, rendering the drug dangerous and ineffective.
Historically, the Thalidomide disaster showed the catastrophic reality of ignoring spatial chemistry and molecular orientation (chirality).
The underground labs supplying the market today prioritize speed of manufacture, high solvent loads to force cheap raws into suspension, and cost optimization above all else. They operate with zero regulatory oversight, zero bio-assays, and absolutely no biological accountability.















































































